Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 10, 2016, Pages 1679-1689

  Wang, Q ^a   Zhang, Y ^a   Yao, X ^b   Xian, H ^a   Liu, Y ^b   Li, H ^b   Chen, H ^a   Wang, X ^a   Wang, R ^a   Zhao, C ^a   Cao, B ^b   Wang, H ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ABDOMINAL INFECTION; ADULT; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CITROBACTER; CITROBACTER FREUNDII; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HOSPITAL MORTALITY; HOSPITAL PATIENT; HUMAN; INVASIVE PROCEDURE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RAOULTELLA; RAOULTELLA PLANTICOLA; RESPIRATORY TRACT INFECTION; SOFT TISSUE INFECTION; SURVIVAL ANALYSIS; SURVIVAL TIME; TRACHEOTOMY; URINARY TRACT INFECTION; WOUND INFECTION; AGED; ANTIBIOTIC RESISTANCE; CHINA; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CASE-CONTROL STUDIES; CHINA; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84978153629     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2710-0     Document Type: Article

References (37)

1. Temkin E, Adler A, Lerner A, Carmeli Y (2014) Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann NY Acad Sci 1323:22–42
2. Queenan AM, Bush K (2007) Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458, Table of contents
3. Nordmann P, Cuzon G, Naas T (2009) The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236
4. Doumith M, Ellington MJ, Livermore DM, Woodford N (2009) Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659–667
5. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ (2014) Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175
6. Gupta N, Limbago BM, Patel JB, Kallen AJ (2011) Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53:60–67
7. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP (2008) Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099–1106
8. Chen S, Feng W, Chen J et al (2014) Spread of carbapenemase-producing enterobacteria in a southwest hospital in China. Ann Clin Microbiol Antimicrob 13:42
9. Kumarasamy KK, Toleman MA, Walsh TR et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602
10. Bogan C, Kaye KS, Chopra T et al (2014) Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. Am J Infect Control 42:612–620
11. Kofteridis DP, Valachis A, Dimopoulou D et al (2014) Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case–control study. J Infect Chemother 20:293–297
12. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y (2008) Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 52:1028–1033
13. Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E (2015) Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect 70:592–599
14. Correa L, Martino MD, Siqueira I et al (2013) A hospital-based matched case–control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 13:80
15. Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM, Lee K (2014) Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis 80:130–135
16. Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A (2011) Antibiotic use and the risk of carbapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case–control study. J Antimicrob Chemother 66:1383–1391
17. Harris AD, Karchmer TB, Carmeli Y, Samore MH (2001) Methodological principles of case–control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 32:1055–1061
18. Kaye KS, Harris AD, Samore M, Carmeli Y (2005) The case-case–control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 26:346–351
19. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ (2013) Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev 26:289–307
20. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS (1992) Selection of controls in case–control studies. I. Principles. Am J Epidemiol 135:1019–1028
21. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS (1992) Selection of controls in case–control studies. II. Types of controls. Am J Epidemiol 135:1029–1041
22. CLSI. Clinical and Laboratory Standards Institute (2014) Performance standards for antimicrobial testing: twentieth informational supplement, CLSI document. M100-S24. Wayne, PA
23. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332
24. Wang X, Li H, Zhao C et al (2014) Novel NDM-9 metallo-beta-lactamase identified from a ST107 Klebsiella pneumoniae strain isolated in China. Int J Antimicrob Agents 44:90–91
25. Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M (2010) Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother 54:573–577
26. Centers for Disease Control and Prevention (CDC) (2013) Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:165–70
27. Hawkey PM, Xiong J, Ye H, Li H, M’Zali FH (2001) Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People’s Republic of China. FEMS Microbiol Lett 194:53–57
28. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ (2007) Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 51:763–765
29. Yu YS, Du XX, Zhou ZH, Chen YG, Li LJ (2006) First isolation of blaIMI-2 in an Enterobacter cloacae clinical isolate from China. Antimicrob Agents Chemother 50:1610–1611
30. Zhang X, Lou D, Xu Y et al (2013) First identification of coexistence of blaNDM-1 and blaCMY-42 among Escherichia coli ST167 clinical isolates. BMC Microbiol 13:282
31. Wang Q, Zhao CJ, Wang H et al (2013) Antimicrobial resistance of gram-negative bacilli isolated from 13 teaching hospitals across China. Zhonghua Yi Xue Za Zhi 93:1388–1396
32. Ahn JY, Song JE, Kim MH et al (2014) Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case–control study. Am J Infect Control 42:621–625
33. Teo J, Cai Y, Tang S et al (2012) Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case–control study. PLoS One 7:e34254
34. Qureshi ZA, Paterson DL, Potoski BA et al (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108–2113
35. Patel TS, Nagel JL (2015) Clinical outcomes of Enterobacteriaceae infections stratified by Carbapenem MICs. J Clin Microbiol 53:201–205
36. Daikos GL, Markogiannakis A (2011) Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 17:1135–1141
37. Axel H, Stephan G (2014) Treatment of infections caused by carbapenem-resistant enterobacteriaceae. Curr Treat Options Infect Dis 4:425–438